Study S000708

An Open-Label Study Examining the Long-Term Safety of Exenatide Given Twice Daily to Patients With Type 2 Diabetes Mellitus

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01876849
Study type: INTERVENTIONAL
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 275
Start: 2003-12
Primary completion: 2008-07
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG:exenatide
Results posted: FALSE

Registered primary outcomes

Long-term safety of twice-daily exenatide treatment, as defined by the occurrence of adverse events. [128 weeks (average treatment period)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.